Charles Schaffer, MD
Ophthalmology · Las Cruces, NMNPI 1962435818
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,374 of the $5,038 with a category attached, or 67.0%. 17 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 28.7% of the total. Reporting peaked in 2019 at $2,622 and has fallen 95.0% since, to $132 in 2025.
Across 57 payments — averaging $88.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$702
- Aerie Pharmaceuticals, Inc.$579
- Bausch & Lomb, A Division Of Bausch Health US, LLC$329
- Kala Pharmaceuticals, Inc.$305
- Rxsight Inc$267
- plus $1K from 11 others
What the payments were for
- Consulting fees$50010%
- Travel & lodging$1,14623%
- Food & beverage$3,37467%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 8 | $1,447 |
| Alcon | 4 | $702 |
| Aerie Pharmaceuticals, Inc. | 11 | $579 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $329 |
| Kala Pharmaceuticals, Inc. | 6 | $305 |
| Rxsight Inc | 3 | $267 |
| Sun Pharmaceutical Industries Inc. | 3 | $266 |
| Novartis | 2 | $222 |
| Bausch & Lomb Americas Inc. | 3 | $141 |
| Glaukos Corporation | 1 | $132 |
| Apellis Pharmaceuticals, Inc. | 1 | $124 |
| AbbVie(2 entities) | 4 | $121 |
| Omeros Corporation | 1 | $121 |
| Ivantis, Inc | 1 | $109 |
| Genentech USA, Inc. | 1 | $81 |
| Ocular Therapeutix, Inc. | 3 | $56 |
| Amgen(2 entities) | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,261
- Tecnis Multifocal Family of 1-piece IOLS$1,261
- Tecnis Symfony IOL$1,261
- Rhopressa$444
- Rocklatan$444
- RXSIGHT CONTACT LENS$249
- RXSIGHT INJECTOR CARTRIDGE$249
- RXSIGHT INJECTOR HANDPIECE$249
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$249
- INVELTYS$237
- VYZULTA$229
- iDoseTR$132
- LIGHT ADJUSTABLE LENS (LAL)$125
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- CEQUA$123
- OMIDRIA$121
- Clareon$120
- BROMSITE$119
- TRAVATAN Z$116
- Hydrus$109
How this compares
$5,038 in reported general payments places this provider in the 80th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 51 | $33,252 |
| RestasisCyclosporine | 20 | $30,749 |
| ProlensaBromfenac Sodium | 74 | $25,335 |
| RhopressaNetarsudil Mesylate | 35 | $18,447 |
| LumiganBimatoprost | 32 | $15,268 |
| VyzultaLatanoprostene Bunod | 16 | $8,080 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $7,200 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 310 | $5,722 |
| Latanoprost | 459 | $5,048 |
| Prednisolone Acetate | 80 | $3,918 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $3,722 |
| Brimonidine Tartrate | 32 | $3,612 |
| Timolol Maleate | 267 | $3,343 |
| Ketorolac Tromethamine | 49 | $821 |
| Dorzolamide Hcl | 15 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $121 | $53,21769 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $579 | $51,69986 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $329 | $25,33574 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $141 | $8,08016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Las Cruces
- Mark GallardoLas Cruces$1.2M
- Edward HernandezLas Cruces$3K
- Robert VillalobosLas Cruces$2K
- Eric WeberLas Cruces$234
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Paul GulbasRuidoso$14K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.